STOCK TITAN

Insmed (INSM) COO exercises options, sells 88,060 preplanned shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Insmed Inc Chief Operating Officer Roger Adsett exercised options to acquire 88,060 shares of common stock at an exercise price of $14.56 per share. On the same date, he sold 88,060 shares in open-market transactions at weighted average prices of $163.18, $164.11, and $164.95 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following these transactions, he directly holds 106,810 shares of Insmed common stock.

Positive

  • None.

Negative

  • None.
Insider Adsett Roger
Role Chief Operating Officer
Sold 88,060 shs ($14.50M)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 88,060 $0.00 --
Exercise Common Stock 88,060 $14.56 $1.28M
Sale Common Stock 6,715 $163.18 $1.10M
Sale Common Stock 19,001 $164.11 $3.12M
Sale Common Stock 62,344 $164.95 $10.28M
Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 194,870 shares (Direct)
Footnotes (1)
  1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 6,715 shares sold at prices ranging from $162.52 to $163.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 19,001 shares sold at prices ranging from $163.52 to $164.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 62,344 shares sold at prices ranging from $164.52 to $165.45 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Options exercised 88,060 shares Stock options exercised into common stock
Option exercise price $14.56 per share Exercise price for 88,060 options
Shares sold 88,060 shares Total common shares sold in open-market trades
Weighted avg sale price block 1 $163.18 per share Weighted average price for 6,715 shares sold
Weighted avg sale price block 2 $164.11 per share Weighted average price for 19,001 shares sold
Weighted avg sale price block 3 $164.95 per share Weighted average price for 62,344 shares sold
Shares held after transactions 106,810 shares Direct Insmed common stock holdings post-transaction
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price financial
"This is the weighted average sales price representing 6,715 shares sold at prices ranging from $162.52 to $163.51 per share"
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
vesting schedule financial
"The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Adsett Roger

(Last)(First)(Middle)
700 US HIGHWAY 202/206

(Street)
BRIDGEWATER NEW JERSEY 08807

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [ INSM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026M(1)88,060A$14.56194,870D
Common Stock04/01/2026S(1)6,715D$163.18(2)188,155D
Common Stock04/01/2026S(1)19,001D$164.11(3)169,154D
Common Stock04/01/2026S(1)62,344D$164.95(4)106,810D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$14.5604/01/2026M(1)88,060 (5)10/03/2026Common Stock88,060$00D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
2. This is the weighted average sales price representing 6,715 shares sold at prices ranging from $162.52 to $163.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
3. This is the weighted average sales price representing 19,001 shares sold at prices ranging from $163.52 to $164.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
4. This is the weighted average sales price representing 62,344 shares sold at prices ranging from $164.52 to $165.45 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
5. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Remarks:
/s/ Roger Adsett, by Michael A. Smith as Attorney-in-fact04/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Insmed (INSM) COO Roger Adsett report in this Form 4?

Roger Adsett exercised stock options for 88,060 Insmed shares at $14.56 each and sold the same number of shares in open-market trades on the same date, while remaining a substantial shareholder with 106,810 shares held directly afterward.

How many Insmed (INSM) shares did the COO sell and at what prices?

He sold 88,060 Insmed common shares in three open-market transactions. The weighted average sale prices were $163.18, $164.11, and $164.95 per share, with detailed price ranges available upon request from the company, the SEC staff, or security holders.

Were Roger Adsett’s Insmed (INSM) share sales pre-planned?

Yes. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on December 3, 2025. Such plans pre-schedule trades, indicating the timing of these sales was arranged in advance rather than decided opportunistically on the trade date.

What stock options did the Insmed (INSM) COO exercise in this filing?

He exercised stock options covering 88,060 shares of Insmed common stock at a $14.56 exercise price. The options vested over four years, with 25% after one year and additional 12.5% portions every six months through the fourth anniversary of the original grant date.

How many Insmed (INSM) shares does the COO own after these transactions?

After exercising options and selling 88,060 shares, Roger Adsett directly holds 106,810 Insmed common shares. This post-transaction balance reflects his remaining equity stake reported in the filing and helps investors gauge the scale of the sale relative to his total holdings.